SeaStar Medical Holding Corporation (ICU)
| Market Cap | 24.82M |
| Revenue (ttm) | 766,000 |
| Net Income (ttm) | -14.67M |
| Shares Out | 27.91M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,045,792 |
| Open | 0.8000 |
| Previous Close | 0.8000 |
| Day's Range | 0.7811 - 0.9050 |
| 52-Week Range | 0.3054 - 6.5000 |
| Beta | -1.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2025 |
About ICU
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, a... [Read more]
Financial Performance
Financial StatementsNews
SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute ...
SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
Trial now over 60% enrolled with 125 of 200 anticipated patients Recent new site activation brings total clinical trial sites to 16 Interim analysis of first 100 patients remains on track for 3Q 2025 ...
SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients
DENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveilla...
SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
Highest Rated Children's Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performance...
SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)
Nationally Recognized Texas Children's Hospital Adds First-In-Class Therapy as a Potential Life-Saving Treatment in Ultra-Rare Cases of Pediatric AKI Nationally Recognized Texas Children's Hospital Ad...
SeaStar Medical Announces Positive Nasdaq Listing Determination
DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ f...
SeaStar Medical Reports Update on Nasdaq Listing Status
DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...
SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
Cincinnati Children's Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy DENVER, June 24, 2025 (GLOBE NE...
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $4 million upfront with up to an additional $4 million of ...
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research
SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (Nasdaq: ICU) announced today that a...
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
Coverage marks SeaStar Medical's second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial
SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript
SeaStar Medical Holding Corporation (NASDAQ:ICU) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jackie Cossmon - IR; WheelHouse Life Science Advisors Eric Schlorff - CE...
SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates
DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing o...
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA Filing Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA Filing
SeaStar Medical to Report First Quarter Financial Results on May 14, 2025
DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...
SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time
DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery
DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award
Company recognized for treatment recently approved in the U.S. for pediatric acute kidney injury (AKI) due to sepsis. NEW YORK , March 18, 2025 /PRNewswire/ -- SeaStar Medical (Nasdaq: ICU) has been s...
SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market
DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced the closing of its previously announced registered direct offering, priced...
SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial
DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hy...